Sandoz launches first and only biosimilar for multiple sclerosis, Tyruko® (natalizumab), in GermanyGlobeNewsWire • 01/31/24
Sandoz announces agreement to acquire CIMERLI® business from Coherus, strengthening position in US marketGlobeNewsWire • 01/22/24
Sandoz launches Hyrimoz® (adalimumab) high-concentration formulation in Europe, aiming to improve patient careGlobeNewsWire • 11/21/23
Sandoz inaugurates new antibiotic production plant in Austria and new biosimilar development center in GermanyGlobeNewsWire • 11/10/23
Novartis delivers 12% sales and 21% core operating income growth from continuing operations (in cc¹). Executes Sandoz spin-off, achieves important innovation milestones, and raises FY 2023 guidanceGlobeNewsWire • 10/24/23
Spin-outs on the rise as companies try to win out in desolate M&A marketProactive Investors • 10/04/23
SDZNY Stock: 7 Things to Know as Novartis Spinoff Sandoz Starts Trading TodayInvestorPlace • 10/04/23
Novartis spin-off completed as Sandoz makes subdued start on Swiss bourseProactive Investors • 10/04/23
Sandoz enters new era as standalone global leader and European champion in generic and biosimilar medicinesGlobeNewsWire • 10/04/23
Novartis executes Sandoz Spin-off, completing strategic transformation into a leading, focused innovative medicines companyGlobeNewsWire • 10/04/23